Joost Sp Vermaat

31PUBLICATIONS
178CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)HaematologyHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (31)

|Aug 05, 2026
First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma.

|Jul 15, 2026
Risk of thrombosis and bleeding following CAR T-cell therapy: Insights from the Dutch "Follow that CAR!" registry.

|Mar 17, 2026
Immunodeficiency-associated primary CNS lymphomas: an International Primary CNS Lymphoma Collaborative Group study.

Leon D Kaulen, Lakshmi Nayak, Philipp Karschnia

|Sep 08, 2025
Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma.

Lorenzo Falchi, Anna Sureda, Sirpa Leppä

|Jul 16, 2025
Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections, and survival after CART in R/R LBCL.

Janneke W de Boer, Kylie Keijzer, Suzanne van Dorp

|Jul 09, 2025
Treatment and outcome of breast implant-associated anaplastic large cell lymphoma: a population-based cohort study in the Netherlands.

Frederik O Meeuwes, Mirian Brink, Marjolein W M van der Poel

Pageof 6

Frequent Collaborators

12 joint publications

Marcel Nijland

7 joint publications

Arjan Diepstra

6 joint publications

F J Sherida H Woei-A-Jin

6 joint publications

Ruben A L de Groen